Seeking Alpha

Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett Syndrome

NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative ...
Business Insider

Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative ...
Nasdaq

Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative ...
Seeking Alpha

Anavex Life Sciences Announces Issuance of New U.S. Patent Expanding ANAVEX®2-73 (blarcamesine) Intellectual Property Portfolio for the Treatment of Hypertension

NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative ...